BR0213659A - Composição, composição farmacêutica, método para produzir imunosupressão, método para reduzir toxidade, método para aumentar a eficiência de um análogo imuno supressor, uso de composição e uso de mistura - Google Patents
Composição, composição farmacêutica, método para produzir imunosupressão, método para reduzir toxidade, método para aumentar a eficiência de um análogo imuno supressor, uso de composição e uso de misturaInfo
- Publication number
- BR0213659A BR0213659A BR0213659-7A BR0213659A BR0213659A BR 0213659 A BR0213659 A BR 0213659A BR 0213659 A BR0213659 A BR 0213659A BR 0213659 A BR0213659 A BR 0213659A
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- isomers
- isa
- mixture
- cyclosporine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
Abstract
"COMPOSIçãO, COMPOSIçãO FARMACêUTICA, MéTODO PARA PRODUZIR IMUNOSUPRESSãO, MéTODO PARA REDUZIR TOXIDADE, MéTODO PARA AUMENTAR A EFICIêNCIA DE UM ANáLOGO IMUNO SUPRESSOR, USO DE COMPOSIçãO E USO DE MISTURA". A invenção refere-se a misturas isoméricas de análogos da ciclosporina que são estruturalmente similares à ciclosporina A. As misturas possuem uma maior eficácia e toxicidade reduzida em relação aos isómeros individuais e em relação às ciclosporinas de ocorrência natural e outros derivados de ciclosporinas atualmente conhecidos. As realizações da presente invenção referem-se a cis- e trans-isómeros dos análogos de ciclosporina A indicados como ISA~ TX~247, e derivados destes. As misturas de isómeros de ISA~ Tx~247 exibem uma combinação de maior potência e toxicidade reduzida em relação às ciclosporinas naturais e atualmente conhecidas. Os isómeros de ISA~ Tx~247 e derivados alquilados, arilados e deuterados são sintetizados pelas vias estereoseletivas onde as condições particulares de uma reação determinam o grau de estereoseletividade. As vias estereoseletivas podem utilizar uma reação de Wittig, ou um reagente organometálico que compreende elementos inorgânicos tais como o boro, silício, titânio, e lítio. A relação dos isómeros em uma mistura pode variar de aproximadamenle 10 a 90 por cento em peso do (E)-isómero a aproximadamente 90 a 10 por cento em peso do (Z)-isómero, com base no peso total da mistura.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34620101P | 2001-10-19 | 2001-10-19 | |
| PCT/CA2002/001560 WO2003033527A2 (en) | 2001-10-19 | 2002-10-17 | Cyclosporine analogue mixtures and their use as immunomodulating agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0213659A true BR0213659A (pt) | 2004-10-26 |
Family
ID=23358378
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0213659-7A BR0213659A (pt) | 2001-10-19 | 2002-10-17 | Composição, composição farmacêutica, método para produzir imunosupressão, método para reduzir toxidade, método para aumentar a eficiência de um análogo imuno supressor, uso de composição e uso de mistura |
Country Status (38)
| Country | Link |
|---|---|
| US (2) | US20110092669A1 (pt) |
| EP (2) | EP1436322B1 (pt) |
| JP (4) | JP2005511538A (pt) |
| KR (1) | KR100992850B1 (pt) |
| CN (1) | CN100344648C (pt) |
| AR (1) | AR036853A1 (pt) |
| AT (1) | ATE401339T1 (pt) |
| AU (1) | AU2002331510B2 (pt) |
| BE (1) | BE2022C547I2 (pt) |
| BR (1) | BR0213659A (pt) |
| CA (2) | CA2460685C (pt) |
| CO (1) | CO5570682A2 (pt) |
| CY (2) | CY1108410T1 (pt) |
| DE (1) | DE60227686D1 (pt) |
| DK (1) | DK1436322T3 (pt) |
| EC (3) | ECSP045060A (pt) |
| ES (1) | ES2310604T3 (pt) |
| FI (1) | FIC20220041I1 (pt) |
| FR (1) | FR22C1051I2 (pt) |
| HK (1) | HK1062567A1 (pt) |
| HR (1) | HRP20040353B1 (pt) |
| IL (2) | IL160762A0 (pt) |
| LT (1) | LTC1436322I2 (pt) |
| MA (1) | MA26337A1 (pt) |
| ME (1) | ME00487B (pt) |
| MX (1) | MXPA04003624A (pt) |
| MY (1) | MY187182A (pt) |
| NL (1) | NL301200I2 (pt) |
| NO (2) | NO331745B1 (pt) |
| NZ (1) | NZ531945A (pt) |
| PL (1) | PL210697B1 (pt) |
| PT (1) | PT1436322E (pt) |
| RU (1) | RU2337106C2 (pt) |
| SI (1) | SI1436322T1 (pt) |
| TN (1) | TNSN04069A1 (pt) |
| UY (1) | UY27502A1 (pt) |
| WO (1) | WO2003033527A2 (pt) |
| ZA (1) | ZA200402270B (pt) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100992850B1 (ko) * | 2001-10-19 | 2010-11-09 | 이소테크니카 인코포레이티드 | 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도 |
| ES2326040T3 (es) | 2001-10-19 | 2009-09-29 | Isotechnika Inc. | Sintesis de analogos de ciclosporina. |
| TW200505946A (en) * | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
| MX2007007262A (es) * | 2004-12-17 | 2007-10-19 | Isotechnika Inc | Metabolitos de analogos de ciclosporina. |
| US7696166B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders |
| US7696165B2 (en) | 2006-03-28 | 2010-04-13 | Albany Molecular Research, Inc. | Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders |
| JP5668476B2 (ja) | 2007-10-08 | 2015-02-12 | オーリニア・ファーマシューティカルズ・インコーポレイテッドＡｕｒｉｎｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | カルシニューリン阻害剤またはｍＴＯＲ阻害剤を含む眼科用組成物 |
| CN102458370A (zh) | 2009-06-09 | 2012-05-16 | 卢克斯生物科技公司 | 用于眼科用途的表面药物递送系统 |
| GB0912584D0 (en) * | 2009-07-20 | 2009-08-26 | Ucl Business Plc | Cyclosporin conjugates |
| RU2630690C9 (ru) | 2010-12-15 | 2017-12-28 | КонтраВир Фармасьютикалз, Инк. | МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ |
| GB201222455D0 (en) | 2012-12-13 | 2013-01-30 | Perioc Ltd | Novel pharmaceutical formulations and their use in the treatment of periodontaldisease |
| EP3549051A4 (en) * | 2016-11-30 | 2020-04-29 | Schrodinger, Inc. | GRAPHIC USER INTERFACE FOR CALCULATING CHEMICAL TRANSITIONAL STATES |
| EP4252629A3 (en) | 2016-12-07 | 2023-12-27 | Biora Therapeutics, Inc. | Gastrointestinal tract detection methods, devices and systems |
| WO2018106928A1 (en) | 2016-12-08 | 2018-06-14 | Contravir Pharmaceuticals, Inc. | Treatment and prevention of hbv diseases by cyclosporine analogue molecules modified at amino acides 1 and 3 |
| EP3554346B1 (en) | 2016-12-14 | 2024-01-31 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with an immunosuppressant |
| US20190224275A1 (en) | 2017-05-12 | 2019-07-25 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US10286036B2 (en) * | 2017-05-12 | 2019-05-14 | Aurinia Pharmaceuticals Inc. | Protocol for treatment of lupus nephritis |
| US20230041197A1 (en) | 2018-06-20 | 2023-02-09 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| EP4201952A1 (en) | 2021-12-21 | 2023-06-28 | Curia Spain, S.A.U. | Process for the controlled synthesis of voclosporin |
| WO2024052941A1 (en) * | 2022-09-09 | 2024-03-14 | Dr. Reddy's Laboratories Limited | Improved process for the preparation of voclosporin |
| WO2024157186A1 (en) * | 2023-01-25 | 2024-08-02 | Procos S.P.A. | New process for the preparation of amorphous voclosporin |
| WO2024157132A1 (en) * | 2023-01-25 | 2024-08-02 | Indena S.P.A. | Process for the preparation of an intermediate useful for the synthesis of voclosporin |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4278545A (en) * | 1979-09-12 | 1981-07-14 | The Bendix Corporation | Apparatus for separating solids and liquid components |
| CH670644A5 (pt) * | 1986-12-18 | 1989-06-30 | Lonza Ag | |
| US5162540A (en) * | 1986-12-18 | 1992-11-10 | Lonza Ltd. | Process for the production of (+) biotin |
| DE3884470T2 (de) * | 1987-06-17 | 1994-03-10 | Sandoz Ag | Cyclosporine und deren Benutzung als Arzneimittel. |
| US5972630A (en) * | 1991-08-19 | 1999-10-26 | Dade Behring Marburg Gmbh | Homogeneous immunoassays using enzyme inhibitors |
| US5750510A (en) * | 1997-04-04 | 1998-05-12 | Abbott Laboratories | 3-descladinose-2,3-anhydroerythromycin derivatives |
| US5939406A (en) * | 1997-07-21 | 1999-08-17 | Wisconsin Alumni Research Foundation | 18-substituted-19-nor-vitamin D compounds |
| ATE314388T1 (de) * | 1997-10-08 | 2006-01-15 | Isotechnika Inc | Deuterierte und undeuterierte cyclosporin-analoga und ihre verwendung als immunmodulierende agentien |
| ES2326040T3 (es) * | 2001-10-19 | 2009-09-29 | Isotechnika Inc. | Sintesis de analogos de ciclosporina. |
| KR100992850B1 (ko) * | 2001-10-19 | 2010-11-09 | 이소테크니카 인코포레이티드 | 시클로스포린 유사체 혼합물 및 면역조절제로서 이들의 용도 |
-
2002
- 2002-10-17 KR KR1020047005721A patent/KR100992850B1/ko active IP Right Grant
- 2002-10-17 NZ NZ531945A patent/NZ531945A/en not_active IP Right Cessation
- 2002-10-17 DK DK02767028T patent/DK1436322T3/da active
- 2002-10-17 RU RU2004110941/04A patent/RU2337106C2/ru active
- 2002-10-17 ES ES02767028T patent/ES2310604T3/es not_active Expired - Lifetime
- 2002-10-17 EP EP02767028A patent/EP1436322B1/en not_active Expired - Lifetime
- 2002-10-17 EP EP07106871A patent/EP1816138A1/en not_active Withdrawn
- 2002-10-17 DE DE60227686T patent/DE60227686D1/de not_active Expired - Lifetime
- 2002-10-17 CA CA2460685A patent/CA2460685C/en not_active Expired - Lifetime
- 2002-10-17 AR ARP020103918A patent/AR036853A1/es not_active Application Discontinuation
- 2002-10-17 UY UY27502A patent/UY27502A1/es not_active Application Discontinuation
- 2002-10-17 MX MXPA04003624A patent/MXPA04003624A/es active IP Right Grant
- 2002-10-17 ME MEP-2008-780A patent/ME00487B/me unknown
- 2002-10-17 CA CA2727642A patent/CA2727642C/en not_active Expired - Lifetime
- 2002-10-17 PL PL370501A patent/PL210697B1/pl unknown
- 2002-10-17 PT PT02767028T patent/PT1436322E/pt unknown
- 2002-10-17 JP JP2003536265A patent/JP2005511538A/ja not_active Withdrawn
- 2002-10-17 MY MYPI20023885A patent/MY187182A/en unknown
- 2002-10-17 AU AU2002331510A patent/AU2002331510B2/en not_active Expired
- 2002-10-17 AT AT02767028T patent/ATE401339T1/de active
- 2002-10-17 IL IL16076202A patent/IL160762A0/xx unknown
- 2002-10-17 SI SI200230742T patent/SI1436322T1/sl unknown
- 2002-10-17 BR BR0213659-7A patent/BR0213659A/pt not_active IP Right Cessation
- 2002-10-17 WO PCT/CA2002/001560 patent/WO2003033527A2/en active IP Right Grant
- 2002-10-17 CN CNB02820798XA patent/CN100344648C/zh not_active Expired - Lifetime
-
2004
- 2004-03-05 IL IL160762A patent/IL160762A/en active IP Right Grant
- 2004-03-23 ZA ZA2004/02270A patent/ZA200402270B/en unknown
- 2004-03-26 MA MA27598A patent/MA26337A1/fr unknown
- 2004-04-14 EC EC2004005060A patent/ECSP045060A/es unknown
- 2004-04-14 EC EC2004005061A patent/ECSP045061A/es unknown
- 2004-04-14 EC EC2004005059A patent/ECSP045059A/es unknown
- 2004-04-16 TN TNP2004000069A patent/TNSN04069A1/en unknown
- 2004-04-19 CO CO04035672A patent/CO5570682A2/es not_active Application Discontinuation
- 2004-04-19 HR HRP20040353AA patent/HRP20040353B1/hr not_active IP Right Cessation
- 2004-05-14 NO NO20042029A patent/NO331745B1/no not_active IP Right Cessation
- 2004-07-22 HK HK04105424A patent/HK1062567A1/xx not_active IP Right Cessation
-
2008
- 2008-10-13 CY CY20081101130T patent/CY1108410T1/el unknown
-
2009
- 2009-06-11 JP JP2009140608A patent/JP5272140B2/ja not_active Expired - Lifetime
-
2010
- 2010-07-02 JP JP2010151859A patent/JP2011006417A/ja active Pending
- 2010-12-23 US US12/977,602 patent/US20110092669A1/en not_active Abandoned
-
2013
- 2013-01-31 JP JP2013017448A patent/JP2013136597A/ja active Pending
-
2014
- 2014-03-18 US US14/217,827 patent/US20140288266A1/en not_active Abandoned
-
2022
- 2022-10-14 LT LTPA2022521C patent/LTC1436322I2/lt unknown
- 2022-10-14 FI FIC20220041C patent/FIC20220041I1/fi unknown
- 2022-10-14 NO NO2022042C patent/NO2022042I1/no unknown
- 2022-10-14 BE BE2022C547C patent/BE2022C547I2/nl unknown
- 2022-10-14 FR FR22C1051C patent/FR22C1051I2/fr active Active
- 2022-10-14 NL NL301200C patent/NL301200I2/nl unknown
- 2022-10-14 CY CY2022030C patent/CY2022030I2/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0213659A (pt) | Composição, composição farmacêutica, método para produzir imunosupressão, método para reduzir toxidade, método para aumentar a eficiência de um análogo imuno supressor, uso de composição e uso de mistura | |
| BR0213658A (pt) | Método para preparar uma mistura isomérica predeterminada ou não dos análogos de ciclosporina a modificados no resìduo de 1-aminoácido, métodopara produzir uma mistura enriquecida com e-isÈmero ou com z-isÈmero de análogos de ciclosporina a modificados no resìduo de 1-aminoácido, mistura de (e) e (z)-isÈmeros, composição, método para a sìntese estereoseletiva do z-isÈmero de isatx247, método para a preparação de aldeìdo do ciclosporina a | |
| JO2034B1 (en) | Isotopes of the hormone peptide its uses and the chemical compounds it contains | |
| IL175319A0 (en) | Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof | |
| WO2004010941A3 (en) | Aqueous 2,6-diisopropylphenol pharmaceutical compositions | |
| AU8336898A (en) | Controlled-release pharmaceutical preparation comprising an ACE inhibitor as active ingredient | |
| YU33004A (sh) | Smeša analoga ciklosporina i njihova upotreba u svojstvu imunomodulatornih supstanci | |
| YU33204A (sh) | Sinteza analoga ciklosporina | |
| Vavrek et al. | Smooth muscle selectivity in bradykinin analogs with multiple D-amino acid substitutions | |
| PT1363656E (pt) | Tripeptideos e derivados de tripeptideos para o tratamento de doencas pos-lesionais do sistema nervoso | |
| MXPA05012655A (es) | Isomeros puros d-(17a)-13 -etil-17-hidroxi -18, 19-dinorpregn- 4-eno-20-ino -3-ona-3e -y ??3z- oxima, asi como el proceso para la sintesis de la mezcla de isomeros y los isomeros puros. | |
| TH95729B (th) | ''ของผสมของสารที่คล้ายไซโคลสปอรีน และการใช้เป็นสารปรับภูมิคุ้มกัน'' | |
| BR0207476A (pt) | Uso de um composto,e, composição farmacêutica | |
| ECSP972347A (es) | Prevencion de la perdida y restauracion de la masa osea por determinados agonistas de prostaglandinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] |
Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI |
|
| B25D | Requested change of name of applicant approved |
Owner name: 697937 ALBERTA LTD. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: PALADIN LABS INC. (CA) |
|
| B25A | Requested transfer of rights approved |
Owner name: ISOTECHNIKA PHARMA INC. (CA) |
|
| B25D | Requested change of name of applicant approved |
Owner name: AURINIA PHARMACEUTICALS INC. (CA) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |